A Case of Combination Therapy for Subretinal Neovascularization in Bilateral Acquired Parafoveal Telangiectasis.

Ryu, Jeong Wan; Kim, Jae Ryun; Lee, Won Ki

doi:2009.50.9.1423

J Korean Ophthalmol Soc > Volume 50(9); 2009 > Article

Case Report

Journal of the Korean Ophthalmological Society 2009;50(9):1423-1426.
DOI: https://doi.org/10.3341/jkos.2009.50.9.1423 Published online September 15, 2009.

A Case of Combination Therapy for Subretinal Neovascularization in Bilateral Acquired Parafoveal Telangiectasis.

Jeong Wan Ryu, Jae Ryun Kim, Won Ki Lee

Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea. wklee@catholic.ac.kr

망막하신생혈관이 동반된 양측 후천성 중심와부근 모세혈관 확장증에서의 복합치료 1예

류정완ㆍ김재련ㆍ이원기

Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea

Abstract

PURPOSE
To evaluate the clinical results of a case of subretinal neovascularization (SRN) in bilateral acquired parafoveal telangiectasis, performed combination therapy of intravitreal bevacizumab (1.25 mg/0.05ml) and photodynamic therapy (PDT). CASE SUMMARY: A 46-year-old female presented with a decrease invisual acuity. Her best-corrected visual acuity (BCVA) was 1.0 in the right eye and 0.1 in the left eye. On ophthalmic examination, she was diagnosed with bilateral acquired parafoveal telangiectasis combined with SRN in the left eye. Intravitreal bevacizumab was injected, and then photodynamic therapy was performed 4 days later. Three months after the combination therapy, her BCVA improved to 0.5, a regression of SRN was observed and vascular leakage was markedly decreased. However, her BCVA decreased to 0.1 and SRN recurred 9 months later. CONCLUSIONS: The combined treatment of intravitreal bevacizumab and photodynamic therapy may be used as a selective alternative treatment modality for SRN in bilateral acquired parafoveal telangiectasis, although its effect is short-term.

Key Words: Bevacizumab;Bilateral acquired parafoveal telangiectasis;Combination therapy;Photodynamic therapy;Subretinal neovascularization